Rivaroxaban Versus Low-molecular-weight Heparin for Preventing Thrombosis in Cancer Patients
Status:
Completed
Trial end date:
2019-04-01
Target enrollment:
Participant gender:
Summary
The study is designed to compare the efficacy and safety of oral rivaroxaban and subcutaneous
low-molecular-weight heparin in preventing femoral venepuncture associated thrombosis among
cancer patients.